Reduction of adhesions using controlled delivery of active oxygen inhibitors

• US 5,785,993 A
• Filed: 07/29/1996
• Issued: 07/28/1998
• Est. Priority Date: 03/24/1995
• Status: Expired due to Term

• Current Assignee: Genzyme Corporation (Sanofi )
• Original Assignee: Focal PLLC
• Inventors: Baker, Keith, Coury, Arthur J.
• Primary Examiner(s): Kishore, Gollamudi S.
• Application Number:
  US08/689,139
• Time in Patent Office: 729 Days
• Field of Search: 424/450, 424/484, 424/489-500, 424/78.08, 514/2, 514/261, 514/944, 514/963, 514/579
• US Class Current: 424/450
• CPC Class Codes: A61K 38/44 Oxidoreductases (1)
• CPC Class Codes: A61K 38/446 Superoxide dismutase (1.15)
• CPC Class Codes: A61K 47/32 Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers , poly(meth)acrylates, or polyvinyl pyrrolidone
• CPC Class Codes: A61K 9/0024 Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

SOD and other active oxygen inhibitors are directly applied in combination with a barrier material at local sites of tissue injury to prevent or decrease formation of adhesions and undesirable proliferation of cells. Preferred barrier materials are polymeric hydrogels providing controlled release of AOI which are directly applied to the afflicted tissue. Examples demonstrate the effects of SOD on pelvic adhesions in the rat when administered by intraperitoneal (I.P.) bolus and by localized sustained release from a topically applied hydrogel system.

Claims

1. A fluent composition for the inhibition of a condition selected from the group consisting of adhesion formation, keloid or hypertrophic scarring, hypertrophy which obstructs ducts, inflammation of joints and endometriosis or for repair of structures selected from the group consisting of arteries, nerve sheaths, the spinal column and spinal disks at a tissue site comprising an effective amount of one or more inhibitors of active oxygen species and a material capable of polymerizing to form a barrier at the tissue site,

wherein the composition is fluent when applied to the tissue site, the material is present in a range of 0.5% to 80% by weight of the composition and the inhibitor is selected from the group consisting of superoxide dismutase, catalase, allopurinol, verapamil, and combinations thereof.

2. The composition of claim 1, further comprising a pharmaceutically acceptable carrier.

3. The composition of claim 1, further comprising means for controlling the release of the inhibitor.

4. The composition of claim 3 wherein the means for controlling the release is the barrier.

5. The composition of claim 3 wherein the means for controlling the release is provided in addition to the barrier.

6. The composition of claim 5 wherein the means for controlled release are selected from the group consisting of microparticles, microcapsules, liposomes, intact or comminuted gels, polymers with the inhibitors releaseably bound thereto, and a complex of an inert salt or organic molecule with the inhibitor.

8. The composition of claim 1, wherein the barrier-forming material is capable of forming a hydrogel.

9. The composition of claim 8, wherein the hydrogel is degradable in vivo.

10. The composition of claim 1, wherein the material is present in a range of 2% to 50% by weight of the composition.

11. The composition of claim 10, wherein the material is present in a range of 4% to 30%.

12. The composition of claim 11, wherein the inhibitor is superoxide dismutase.

13. The composition of claim 1 further comprising a biologically active compound other than active oxygen inhibitors.

28. The composition of claim 1 wherein the barrier is a polyethylene glycol oligolactide diacrylate.

7. A composition for inhibition of a condition selected from the group consisting of adhesion formation, keloid or hypertrophic scarring, hypertrophy which obstructs ducts, inflammation of joints and endometriosis or for repair of structures selected from the group consisting of arteries, nerve sheaths, the spinal column and spinal disks at a tissue site comprising an effective amount of one or more inhibitors of active oxygen species and a material which is fluent when applied to the tissue site and is polymerized at the tissue site to form a barrier at the tissue site,

wherein the material is present in a range of 0.5% to 80% by weight of the composition and the inhibitor is selected from the group consisting of superoxide dismutase, catalase, allopurinol, verapamil, and combinations thereof.

14. A method for the inhibition of a condition selected from the group consisting of adhesion formation, keloid or hypertrophic scarring, hypertrophy which obstructs ducts, inflammation of joints and endometriosis or for repair of structures selected from the group consisting of arteries, nerve sheaths, the spinal column and spinal disks comprising administering a fluent composition comprising an effective amount of at least one inhibitor of active oxygen species in combination with a material capable of polymerizing to form a barrier at the tissue site,

wherein the material is present in a range of 0.5% to 80% by weight of the composition and the inhibitor is selected from the group consisting of superoxide dismutase, catalase, allopurinol, verapamil, and combinations thereof.

15. The method of claim 14 further comprising administering the composition in a pharmaceutically acceptable carrier.

16. The method of claim 14, wherein the proliferation to be inhibited is the formation of an adhesion.

17. The method of claim 16, wherein the adhesion is a secondary adhesion.

18. The method of claim 14 wherein the inhibitor is selected from the group consisting of superoxide dismutase, catalase, allopurinol, verapamil, and combinations thereof.

19. The method of claim 18, wherein the inhibitor is superoxide dismutase.

20. The method of claim 14, further comprising administering at the site means for controlling the release of the inhibitor.

21. The method of claim 14, wherein the barrier is a hydrogel.

22. The method of claim 14 further comprising administering at the site with the active oxygen inhibitors biologically active molecules that are not active oxygen inhibitors.

23. The method of claim 21 wherein the release controlling means is the hydrogel.

24. The method of claim 14 further comprising permitting the material to polymerize to form a barrier at the tissue site comprising the inhibitor, wherein the barrier inhibits cell proliferation at the tissue site.

25. The method of claim 24 wherein the barrier inhibits tissue adhesion at the site.

26. The method of claim 24 wherein the barrier is a hydrogel.

27. The method of claim 14 wherein the cell proliferation to be inhibited occurs in a condition selected from the group consisting of restenosis, keloid scarring, hypertrophic scarring, hypertrophic duct obstruction, benign prostatic hypertrophy and endometriosis.

29. The method of claim 14 wherein the barrier is a polyethylene glycol oligolactide diacrylate.

30. A method of inhibiting secondary adhesion formation after adhesiolysis of an adhesion on a tissue site, comprising administering to the site a fluent composition comprising an effective amount of at least one inhibitor of active oxygen species in combination with a material capable of polymerizing to form a barrier at the tissue site,

wherein the material is present in a range of 0.5% to 80% by weight of the composition and the inhibitor is selected from the group consisting of superoxide dismutase, catalase, allopurinol, verapamil, and combinations thereof.

31. The method of claim 30 further comprising administering the composition in a pharmaceutically acceptable carrier.

32. The method of claim 30 wherein the proliferation to be inhibited is the formation of a secondary adhesion.

33. The method of claim 30 wherein the inhibitor is selected from the group consisting of superoxide dismutase, catalase, allopurinol, verapamil, and combinations thereof.

34. The method of claim 30 wherein the inhibitor is superoxide dismutase.

35. The method of claim 30 further comprising administering at the site means for controlling the release of the inhibitor.

36. The method of claim 30 wherein the barrier is a hydrogel.

37. The method of claim 30 wherein the composition further comprises biologically active molecules that are not active oxygen inhibitors.

38. The method of claim 35 wherein the barrier is the release controlling means.

39. The method of claim 38 wherein the barrier is a hydrogel.

40. The method of claim 30 further comprising polymerizing the material to form a barrier comprising the inhibitor at the tissue site.

41. The method of claim 30 wherein the barrier inhibits tissue adhesion at the site.

42. The method of claim 30 wherein the barrier is a polyethylene glycol oligolactide diacrylate.